Work

Immunoinformatic-driven design of a multi-epitope vaccine against Helicobacter pylori

Year: 2026

Type: article

Abstract: Helicobacter pylori (H. pylori) is present in the gastric mucosa of approximately half of the global population and is classified as a definitive type I carcinogen. Developing a logical and effective vaccine against H. pylori remains a critical need. To enhance immune protection, a multi-epitope vaccine was designed using an immunoinformatic-driven approach. The genome of the pathogen was analyzed to identify potential epitopes using several algorithms for predicting T-cell and B-cell epitopes. The resulting multi-epitope vaccine was evaluated for antigenicity, allergenicity, and physicochemical properties. The tertiary structure was predicted and validated using a Ramachandran plot. Molecular docking analysis revealed favorable interactions between the vaccine and immune receptors, while molecular dynamics simulations performed with GROMACS confirmed the stability of these interactions through key dynamic indexes. Additionally, immune simulations, codon optimization, and in silico cloning were conducted to further evaluate the vaccine candidate. In silico predictions indicate that the proposed vaccine construct may be safe and stable, holding promise as an effective measure against H. pylori -induced gastric inflammation. Schematic overview of the vaccine design process for Helicobacter pylori . The diagram illustrates the key stages and evaluations performed to develop the final vaccine candidate. • Multi-epitope vaccine design against H. pylori using immunoinformatic for enhanced immune protection. • Comprehensive epitope screening using advanced algorithms for T-cell and B-cell epitope prediction. • Stable and non-allergenic vaccine candidate with favorable antigenicity and physicochemical properties. • Molecular docking and dynamics simulations confirm strong binding and stability with immune receptors. • In silico immune simulations, codon optimization, and cloning support vaccine efficacy and feasibility.

Source: Biochemistry and Biophysics Reports

DOI: 10.1016/j.bbrep.2026.102498